
|Articles|April 26, 2004
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: The evolution of eye care on display at AAO 2025
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
Ocular pickleball injuries rise sharply with increasing game popularity
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5